Clinical Benefit and Safety of Reduced Elective Dose in Definitive Radiotherapy for Head and Neck Squamous Cell Carcinoma: The UPGRADE-RT Multicenter Randomized Controlled Trial
Authors:
- Sven van Den BoschSBSven van Den Bosch
- Maurice C. CoxMCMaurice C. Cox
- Gerjon HanninkGHGerjon Hannink
- Johannes H.A.M. KaandersJKJohannes H.A.M. Kaanders
- On Behalf Of The Dutch Head And Neck SocietyOSOn Behalf Of The Dutch Head And Neck Society
Open Access
- 10 August 2025
- journal article
- Published by American Society of Clinical Oncology (ASCO) in Journal of Clinical Oncology
- Vol. 43 (23) , 2583-2594
Abstract
PURPOSE: Definitive radiotherapy (RT) for head and neck cancer (HNC) has significant long-term toxicity with elective neck irradiation (ENI) as a major contributor. In this multicenter randomized trial, the clinical benefit and safety of definitive RT with reduced versus standard elective dose were compared. METHODS: Newly diagnosed patients with cT2-4N0-2M0 HNC were accrued and treated in five Dutch centers (definitive accelerated RT, 68 Gy in 34 fractions in 5.5 weeks). Patients receiving concurrent chemotherapy were not eligible. Dose for ENI was randomly assigned (2:1; dose reduction, 43 Gy, versus control, 50 Gy). The primary outcome was normalcy of diet score at 1 year. The secondary outcome was recurrence in electively irradiated nodes at 2 years in the dose reduction group with the null hypothesis rejected if the upper-bound one-sided 95% CI exceeded 9%. RESULTS: Between 2016 and 2022, 300 patients were randomnly assigned, of whom 295 were evaluable and included in analysis (dose reduction, 196 and control, 99). The mean normalcy of diet score at 1 year was 91.6 (95% CI, 88.5 to 94.7) in the dose reduction group and 92.6 (95% CI, 88.2 to 97.1) in the control group (mean difference, –1.1 [95% CI, –6.5 to 4.4]). The 2-year recurrence rate in electively irradiated nodes in the dose reduction group was 4.9% (upper-bound one-sided 95% CI, 7.5%). In the control group, this was 4.3% (upper bound one-sided 95% CI, 7.7%). Exploratory analyses demonstrated less acute dysphagia grade ≥3 and better xerostomia-related quality of life in the dose reduction group. CONCLUSION: This is the second randomized controlled trial demonstrating that reduced elective dose is safe in definitive RT for HNC.Keywords
This publication has 26 references indexed in Scilit:
- Minimization in randomized clinical trialsStatistics in Medicine, 2023
- Comparison of Patients With Head and Neck Cancer in Randomized Clinical Trials and Clinical PracticeJAMA Otolaryngology–Head & Neck Surgery, 2022
- Squamous cell carcinoma of the oral cavity, larynx, oropharynx and hypopharynx: EHNS–ESMO–ESTRO Clinical Practice Guidelines for diagnosis, treatment and follow-upAnnals of Oncology, 2020
- Targeted Intervention to Improve the Quality of Head and Neck Radiation Therapy Treatment Planning in the Netherlands: Short and Long-Term ImpactInternational Journal of Radiation Oncology - Biology - Physics (IJROBP), 2019
- EANM/EARL FDG-PET/CT accreditation - summary results from the first 200 accredited imaging systemsEuropean Journal of Nuclear Medicine and Molecular Imaging, 2017
- Patterns of Recurrence in Electively Irradiated Lymph Node Regions After Definitive Accelerated Intensity Modulated Radiation Therapy for Head and Neck Squamous Cell CarcinomaInternational Journal of Radiation Oncology - Biology - Physics (IJROBP), 2016
- FDG PET/CT: EANM procedure guidelines for tumour imaging: version 2.0European Journal of Nuclear Medicine and Molecular Imaging, 2014
- The impact of late treatment-toxicity on generic health-related quality of life in head and neck cancer patients after radiotherapyOral Oncology, 2011
- Dose-response relationship for radiation therapy of subclinical diseaseInternational Journal of Radiation Oncology - Biology - Physics (IJROBP), 1995
- A performance status scale for head and neck cancer patientsCancer, 1990